Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
D000085:Acetates / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D002210:Caprylates / Q000378:metabolism; D002784:Cholesterol / Q000096:biosynthesis*; D005227:Fatty Acids / Q000096:biosynthesis; D005704:Gallbladder / Q000378:metabolism; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D066298:In Vitro Techniques; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D007783:Lactones / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008148:Lovastatin / Q000031:analogs & derivatives; D008297:Male; D008798:Mevalonic Acid / Q000378:metabolism; D051379:Mice; D009281:Naphthalenes / Q000494:pharmacology*; D009284:Naphthols; D009928:Organ Specificity; D011714:Pyrans / Q000494:pharmacology; D051381:Rats; D013261:Sterols / Q000096:biosynthesis
D000085:Acetates; D002210:Caprylates; D005227:Fatty Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007783:Lactones; D009281:Naphthalenes; D009284:Naphthols; D011714:Pyrans; D013261:Sterols; C012258:mevastatin; C013749:ML 236A; D002784:Cholesterol; D008148:Lovastatin; D008798:Mevalonic Acid